APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Biosimilar Monoclonal Antibodies

Monoclonal antibodies (mAb) are antibodies produced by using identical immune cells that are clones of one unique parent cell. Since monoclonal antibodies are produced from clones of only one parent cell, all monoclonal antibodies produced by the parent cell are the same due to which, they are called biosimilar monoclonal antibodies.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Monoclonal antibodies (mAb) are antibodies produced by using identical immune cells that are clones of one unique parent cell. Since monoclonal antibodies are produced from clones of only one parent cell, all monoclonal antibodies produced by the parent cell are the same due to which, they are called biosimilar monoclonal antibodies.

Biosimilar Monoclonal Antibodies refer to the biologic medical product that are almost an identical copy of the original monoclonal antibodies but manufactured by a different company.

Selected research

Market Analysis & Forecast

Global Biosimilar Monoclonal Antibodies Market Analysis and Forecast 2026-2032

Report ID 173970940221 December 2025190 pages

Choose your research edition.

Industry ResearchBiosimilar Monoclonal Antibodies Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal Biosimilar Monoclonal Antibodies Industry Growth and Trends Forecast to 203293 pages · $3,450 USDMarket StructureGlobal Biosimilar Monoclonal Antibodies Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032182 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Biosimilar Monoclonal Antibodies Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Biosimilar Monoclonal Antibodies Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

Monoclonal antibodies (mAb) are antibodies produced by using identical immune cells that are clones of one unique parent cell. Since monoclonal antibodies are produced from clones of only one parent cell, all monoclonal antibodies produced by the parent cell are the same due to which, they are called biosimilar monoclonal antibodies.

Biosimilar Monoclonal Antibodies refer to the biologic medical product that are almost an identical copy of the original monoclonal antibodies but manufactured by a different company.

Global Biosimilar Monoclonal Antibodies key players include Celltrion, 3SBIO, Pfizer (Hospira), Novartis (Sandoz), etc. Global top four manufacturers hold a share nearly 85%.

Read the full market overview

Europe is the largest market, with a share about 40%, followed by China, and United States, both have a share about 50 percent.

In terms of product, Infliximab is the largest segment, with a share nearly 40%. And in terms of application, the largest application is Autoimmune Disease, followed by Oncology, etc.

This report presents an overview of global market for Biosimilar Monoclonal Antibodies, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Biosimilar Monoclonal Antibodies, also provides the sales of main regions and countries. Of the upcoming market potential for Biosimilar Monoclonal Antibodies, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Biosimilar Monoclonal Antibodies sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Biosimilar Monoclonal Antibodies market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Biosimilar Monoclonal Antibodies sales, projected growth trends, production technology, application and end-user industry.

Biosimilar Monoclonal Antibodies Segment by Company

Celltrion

Pfizer (Hospira)

3SBIO

Novartis (Sandoz)

Dr Reddy’s

Celgen Biopharma

Cadila Healthcare

Hisun Pharma

Torrent Pharmaceuticals

Biosimilar Monoclonal Antibodies Segment by Type

Infliximab

Rituximab

Trastuzumab

Adalimumab

Other

Biosimilar Monoclonal Antibodies Segment by Application

Oncology

Autoimmune Disease

Other

Biosimilar Monoclonal Antibodies Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Biosimilar Monoclonal Antibodies market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Biosimilar Monoclonal Antibodies and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Biosimilar Monoclonal Antibodies.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Biosimilar Monoclonal Antibodies in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Biosimilar Monoclonal Antibodies manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Biosimilar Monoclonal Antibodies sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Biosimilar Monoclonal Antibodies Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Infliximab Major Manufacturers Table 3. Rituximab Major Manufacturers Table 4. Trastuzumab Major Manufacturers Table 5. Adalimumab Major Manufacturers Table 6. Other Major Manufacturers Table 7. Global Biosimilar Monoclonal Antibodies Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 8. Oncology Major Manufacturers Table 9. Autoimmune Disease Major Manufacturers Table 10. Other Major Manufacturers Table 11. Biosimilar Monoclonal Antibodies Industry Trends Table 12. Biosimilar Monoclonal Antibodies Industry Drivers Table 13. Biosimilar Monoclonal Antibodies Industry Opportunities and Challenges Table 14. Biosimilar Monoclonal Antibodies Industry Restraints Table 15. Global Biosimilar Monoclonal Antibodies Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 16. Global Biosimilar Monoclonal Antibodies Revenue by Region (2021-2026) & (US$ Million) Table 17. Global Biosimilar Monoclonal Antibodies Revenue by Region (2027-2032) & (US$ Million) Table 18. Global Biosimilar Monoclonal Antibodies Revenue Market Share by Region (2021-2026) Table 19. Global Biosimilar Monoclonal Antibodies Revenue Market Share by Region (2027-2032) Table 20. Global Biosimilar Monoclonal Antibodies Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (K Units) Table 21. Global Biosimilar Monoclonal Antibodies Sales by Region (2021-2026) & (K Units) Table 22. Global Biosimilar Monoclonal Antibodies Sales by Region (2027-2032) & (K Units) Table 23. Global Biosimilar Monoclonal Antibodies Sales Market Share by Region (2021-2026) Table 24. Global Biosimilar Monoclonal Antibodies Sales Market Share by Region (2027-2032) Table 25. Global Biosimilar Monoclonal Antibodies Revenue by Manufacturers (US$ Million) & (2021-2026) Table 26. Global Biosimilar Monoclonal Antibodies Revenue Market Share by Manufacturers (2021-2026) Table 27. Global Biosimilar Monoclonal Antibodies Sales by Manufacturers (US$ Million) & (2021-2026) Table 28. Global Biosimilar Monoclonal Antibodies Sales Market Share by Manufacturers (2021-2026) Table 29. Global Biosimilar Monoclonal Antibodies Sales Price (USD/Unit) of Manufacturers (2021-2026) Table 30. Global Biosimilar Monoclonal Antibodies Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 31. Global Biosimilar Monoclonal Antibodies Key Manufacturers Manufacturing Sites & Headquarters Table 32. Global Biosimilar Monoclonal Antibodies Manufacturers, Product Type & Application Table 33. Global Biosimilar Monoclonal Antibodies Manufacturers' Establishment Date Table 34. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 35. Global Biosimilar Monoclonal Antibodies by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 36. Global Biosimilar Monoclonal Antibodies Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Biosimilar Monoclonal Antibodies Revenue by Type (2021-2026) & (US$ Million) Table 38. Global Biosimilar Monoclonal Antibodies Revenue by Type (2027-2032) & (US$ Million) Table 39. Global Biosimilar Monoclonal Antibodies Revenue Market Share by Type (2021-2026) Table 40. Global Biosimilar Monoclonal Antibodies Revenue Market Share by Type (2027-2032) Table 41. Global Biosimilar Monoclonal Antibodies Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 42. Global Biosimilar Monoclonal Antibodies Sales by Type (2021-2026) & (K Units) Table 43. Global Biosimilar Monoclonal Antibodies Sales by Type (2027-2032) & (K Units) Table 44. Global Biosimilar Monoclonal Antibodies Sales Market Share by Type (2021-2026) Table 45. Global Biosimilar Monoclonal Antibodies Sales Market Share by Type (2027-2032) Table 46. Global Biosimilar Monoclonal Antibodies Price by Type (2021-2026) & (USD/Unit) Table 47. Global Biosimilar Monoclonal Antibodies Price by Type (2027-2032) & (USD/Unit) Table 48. Global Biosimilar Monoclonal Antibodies Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 49. Global Biosimilar Monoclonal Antibodies Revenue by Application (2021-2026) & (US$ Million) Table 50. Global Biosimilar Monoclonal Antibodies Revenue by Application (2027-2032) & (US$ Million) Table 51. Global Biosimilar Monoclonal Antibodies Revenue Market Share by Application (2021-2026) Table 52. Global Biosimilar Monoclonal Antibodies Revenue Market Share by Application (2027-2032) Table 53. Global Biosimilar Monoclonal Antibodies Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 54. Global Biosimilar Monoclonal Antibodies Sales by Application (2021-2026) & (K Units) Table 55. Global Biosimilar Monoclonal Antibodies Sales by Application (2027-2032) & (K Units) Table 56. Global Biosimilar Monoclonal Antibodies Sales Market Share by Application (2021-2026) Table 57. Global Biosimilar Monoclonal Antibodies Sales Market Share by Application (2027-2032) Table 58. Global Biosimilar Monoclonal Antibodies Price by Application (2021-2026) & (USD/Unit) Table 59. Global Biosimilar Monoclonal Antibodies Price by Application (2027-2032) & (USD/Unit) Table 60. Celltrion Company Information Table 61. Celltrion Business Overview Table 62. Celltrion Biosimilar Monoclonal Antibodies Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 63. Celltrion Biosimilar Monoclonal Antibodies Product Portfolio Table 64. Celltrion Recent Development Table 65. Pfizer (Hospira) Company Information Table 66. Pfizer (Hospira) Business Overview Table 67. Pfizer (Hospira) Biosimilar Monoclonal Antibodies Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 68. Pfizer (Hospira) Biosimilar Monoclonal Antibodies Product Portfolio Table 69. Pfizer (Hospira) Recent Development Table 70. 3SBIO Company Information Table 71. 3SBIO Business Overview Table 72. 3SBIO Biosimilar Monoclonal Antibodies Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 73. 3SBIO Biosimilar Monoclonal Antibodies Product Portfolio Table 74. 3SBIO Recent Development Table 75. Novartis (Sandoz) Company Information Table 76. Novartis (Sandoz) Business Overview Table 77. Novartis (Sandoz) Biosimilar Monoclonal Antibodies Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 78. Novartis (Sandoz) Biosimilar Monoclonal Antibodies Product Portfolio Table 79. Novartis (Sandoz) Recent Development Table 80. Dr Reddy’s Company Information Table 81. Dr Reddy’s Business Overview Table 82. Dr Reddy’s Biosimilar Monoclonal Antibodies Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 83. Dr Reddy’s Biosimilar Monoclonal Antibodies Product Portfolio Table 84. Dr Reddy’s Recent Development Table 85. Celgen Biopharma Company Information Table 86. Celgen Biopharma Business Overview Table 87. Celgen Biopharma Biosimilar Monoclonal Antibodies Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 88. Celgen Biopharma Biosimilar Monoclonal Antibodies Product Portfolio Table 89. Celgen Biopharma Recent Development Table 90. Cadila Healthcare Company Information Table 91. Cadila Healthcare Business Overview Table 92. Cadila Healthcare Biosimilar Monoclonal Antibodies Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 93. Cadila Healthcare Biosimilar Monoclonal Antibodies Product Portfolio Table 94. Cadila Healthcare Recent Development Table 95. Hisun Pharma Company Information Table 96. Hisun Pharma Business Overview Table 97. Hisun Pharma Biosimilar Monoclonal Antibodies Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 98. Hisun Pharma Biosimilar Monoclonal Antibodies Product Portfolio Table 99. Hisun Pharma Recent Development Table 100. Torrent Pharmaceuticals Company Information Table 101. Torrent Pharmaceuticals Business Overview Table 102. Torrent Pharmaceuticals Biosimilar Monoclonal Antibodies Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 103. Torrent Pharmaceuticals Biosimilar Monoclonal Antibodies Product Portfolio Table 104. Torrent Pharmaceuticals Recent Development Table 105. North America Biosimilar Monoclonal Antibodies Revenue by Type (2021-2026) & (US$ Million) Table 106. North America Biosimilar Monoclonal Antibodies Revenue by Type (2027-2032) & (US$ Million) Table 107. North America Biosimilar Monoclonal Antibodies Sales by Type (2021-2026) & (K Units) Table 108. North America Biosimilar Monoclonal Antibodies Sales by Type (2027-2032) & (K Units) Table 109. North America Biosimilar Monoclonal Antibodies Sales Price by Type (2021-2026) & (USD/Unit) Table 110. North America Biosimilar Monoclonal Antibodies Sales Price by Type (2027-2032) & (USD/Unit) Table 111. North America Biosimilar Monoclonal Antibodies Revenue by Application (2021-2026) & (US$ Million) Table 112. North America Biosimilar Monoclonal Antibodies Revenue by Application (2027-2032) & (US$ Million) Table 113. North America Biosimilar Monoclonal Antibodies Sales by Application (2021-2026) & (K Units) Table 114. North America Biosimilar Monoclonal Antibodies Sales by Application (2027-2032) & (K Units) Table 115. North America Biosimilar Monoclonal Antibodies Sales Price by Application (2021-2026) & (USD/Unit) Table 116. North America Biosimilar Monoclonal Antibodies Sales Price by Application (2027-2032) & (USD/Unit) Table 117. North America Biosimilar Monoclonal Antibodies Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 118. North America Biosimilar Monoclonal Antibodies Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 119. North America Biosimilar Monoclonal Antibodies Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 120. North America Biosimilar Monoclonal Antibodies Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 121. North America Biosimilar Monoclonal Antibodies Sales by Country (2021-2026) & (K Units) Table 122. North America Biosimilar Monoclonal Antibodies Sales by Country (2027-2032) & (K Units) Table 123. North America Biosimilar Monoclonal Antibodies Sales Price by Country (2021-2026) & (USD/Unit) Table 124. North America Biosimilar Monoclonal Antibodies Sales Price by Country (2027-2032) & (USD/Unit) Table 125. United States Biosimilar Monoclonal Antibodies Revenue (2021-2032) & (US$ Million) Table 126. Canada Biosimilar Monoclonal Antibodies Revenue (2021-2032) & (US$ Million) Table 127. Mexico Biosimilar Monoclonal Antibodies Revenue (2021-2032) & (US$ Million) Table 128. Europe Biosimilar Monoclonal Antibodies Revenue by Type (2021-2026) & (US$ Million) Table 129. Europe Biosimilar Monoclonal Antibodies Revenue by Type (2027-2032) & (US$ Million) Table 130. Europe Biosimilar Monoclonal Antibodies Sales by Type (2021-2026) & (K Units) Table 131. Europe Biosimilar Monoclonal Antibodies Sales by Type (2027-2032) & (K Units) Table 132. Europe Biosimilar Monoclonal Antibodies Sales Price by Type (2021-2026) & (USD/Unit) Table 133. Europe Biosimilar Monoclonal Antibodies Sales Price by Type (2027-2032) & (USD/Unit) Table 134. Europe Biosimilar Monoclonal Antibodies Revenue by Application (2021-2026) & (US$ Million) Table 135. Europe Biosimilar Monoclonal Antibodies Revenue by Application (2027-2032) & (US$ Million) Table 136. Europe Biosimilar Monoclonal Antibodies Sales by Application (2021-2026) & (K Units) Table 137. Europe Biosimilar Monoclonal Antibodies Sales by Application (2027-2032) & (K Units) Table 138. Europe Biosimilar Monoclonal Antibodies Sales Price by Application (2021-2026) & (USD/Unit) Table 139. Europe Biosimilar Monoclonal Antibodies Sales Price by Application (2027-2032) & (USD/Unit) Table 140. Europe Biosimilar Monoclonal Antibodies Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 141. Europe Biosimilar Monoclonal Antibodies Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 142. Europe Biosimilar Monoclonal Antibodies Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 143. Europe Biosimilar Monoclonal Antibodies Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 144. Europe Biosimilar Monoclonal Antibodies Sales by Country (2021-2026) & (K Units) Table 145. Europe Biosimilar Monoclonal Antibodies Sales by Country (2027-2032) & (K Units) Table 146. Europe Biosimilar Monoclonal Antibodies Sales Price by Country (2021-2026) & (USD/Unit) Table 147. Europe Biosimilar Monoclonal Antibodies Sales Price by Country (2027-2032) & (USD/Unit) Table 148. Germany Biosimilar Monoclonal Antibodies Revenue (2021-2032) & (US$ Million) Table 149. France Biosimilar Monoclonal Antibodies Revenue (2021-2032) & (US$ Million) Table 150. U.K. Biosimilar Monoclonal Antibodies Revenue (2021-2032) & (US$ Million) Table 151. Italy Biosimilar Monoclonal Antibodies Revenue (2021-2032) & (US$ Million) Table 152. Russia Biosimilar Monoclonal Antibodies Revenue (2021-2032) & (US$ Million) Table 153. Spain Biosimilar Monoclonal Antibodies Revenue (2021-2032) & (US$ Million) Table 154. Netherlands Biosimilar Monoclonal Antibodies Revenue (2021-2032) & (US$ Million) Table 155. Switzerland Biosimilar Monoclonal Antibodies Revenue (2021-2032) & (US$ Million) Table 156. Sweden Biosimilar Monoclonal Antibodies Revenue (2021-2032) & (US$ Million) Table 157. Poland Biosimilar Monoclonal Antibodies Revenue (2021-2032) & (US$ Million) Table 158. China Biosimilar Monoclonal Antibodies Revenue by Type (2021-2026) & (US$ Million) Table 159. China Biosimilar Monoclonal Antibodies Revenue by Type (2027-2032) & (US$ Million) Table 160. China Biosimilar Monoclonal Antibodies Sales by Type (2021-2026) & (K Units) Table 161. China Biosimilar Monoclonal Antibodies Sales by Type (2027-2032) & (K Units) Table 162. China Biosimilar Monoclonal Antibodies Sales Price by Type (2021-2026) & (USD/Unit) Table 163. China Biosimilar Monoclonal Antibodies Sales Price by Type (2027-2032) & (USD/Unit) Table 164. China Biosimilar Monoclonal Antibodies Revenue by Application (2021-2026) & (US$ Million) Table 165. China Biosimilar Monoclonal Antibodies Revenue by Application (2027-2032) & (US$ Million) Table 166. China Biosimilar Monoclonal Antibodies Sales by Application (2021-2026) & (K Units) Table 167. China Biosimilar Monoclonal Antibodies Sales by Application (2027-2032) & (K Units) Table 168. China Biosimilar Monoclonal Antibodies Sales Price by Application (2021-2026) & (USD/Unit) Table 169. China Biosimilar Monoclonal Antibodies Sales Price by Application (2027-2032) & (USD/Unit) Table 170. Asia Biosimilar Monoclonal Antibodies Revenue by Type (2021-2026) & (US$ Million) Table 171. Asia Biosimilar Monoclonal Antibodies Revenue by Type (2027-2032) & (US$ Million) Table 172. Asia Biosimilar Monoclonal Antibodies Sales by Type (2021-2026) & (K Units) Table 173. Asia Biosimilar Monoclonal Antibodies Sales by Type (2027-2032) & (K Units) Table 174. Asia Biosimilar Monoclonal Antibodies Sales Price by Type (2021-2026) & (USD/Unit) Table 175. Asia Biosimilar Monoclonal Antibodies Sales Price by Type (2027-2032) & (USD/Unit) Table 176. Asia Biosimilar Monoclonal Antibodies Revenue by Application (2021-2026) & (US$ Million) Table 177. Asia Biosimilar Monoclonal Antibodies Revenue by Application (2027-2032) & (US$ Million) Table 178. Asia Biosimilar Monoclonal Antibodies Sales by Application (2021-2026) & (K Units) Table 179. Asia Biosimilar Monoclonal Antibodies Sales by Application (2027-2032) & (K Units) Table 180. Asia Biosimilar Monoclonal Antibodies Sales Price by Application (2021-2026) & (USD/Unit) Table 181. Asia Biosimilar Monoclonal Antibodies Sales Price by Application (2027-2032) & (USD/Unit) Table 182. Asia Biosimilar Monoclonal Antibodies Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 183. Asia Biosimilar Monoclonal Antibodies Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 184. Asia Biosimilar Monoclonal Antibodies Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 185. Asia Biosimilar Monoclonal Antibodies Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 186. Asia Biosimilar Monoclonal Antibodies Sales by Country (2021-2026) & (K Units) Table 187. Asia Biosimilar Monoclonal Antibodies Sales by Country (2027-2032) & (K Units) Table 188. Asia Biosimilar Monoclonal Antibodies Sales Price by Country (2021-2026) & (USD/Unit) Table 189. Asia Biosimilar Monoclonal Antibodies Sales Price by Country (2027-2032) & (USD/Unit) Table 190. Japan Biosimilar Monoclonal Antibodies Revenue (2021-2032) & (US$ Million) Table 191. South Korea Biosimilar Monoclonal Antibodies Revenue (2021-2032) & (US$ Million) Table 192. India Biosimilar Monoclonal Antibodies Revenue (2021-2032) & (US$ Million) Table 193. Australia Biosimilar Monoclonal Antibodies Revenue (2021-2032) & (US$ Million) Table 194. Taiwan Biosimilar Monoclonal Antibodies Revenue (2021-2032) & (US$ Million) Table 195. Southeast Asia Biosimilar Monoclonal Antibodies Revenue (2021-2032) & (US$ Million) Table 196. SAMEA Biosimilar Monoclonal Antibodies Revenue by Type (2021-2026) & (US$ Million) Table 197. SAMEA Biosimilar Monoclonal Antibodies Revenue by Type (2027-2032) & (US$ Million) Table 198. SAMEA Biosimilar Monoclonal Antibodies Sales by Type (2021-2026) & (K Units) Table 199. SAMEA Biosimilar Monoclonal Antibodies Sales by Type (2027-2032) & (K Units) Table 200. SAMEA Biosimilar Monoclonal Antibodies Sales Price by Type (2021-2026) & (USD/Unit) Table 201. SAMEA Biosimilar Monoclonal Antibodies Sales Price by Type (2027-2032) & (USD/Unit) Table 202. SAMEA Biosimilar Monoclonal Antibodies Revenue by Application (2021-2026) & (US$ Million) Table 203. SAMEA Biosimilar Monoclonal Antibodies Revenue by Application (2027-2032) & (US$ Million) Table 204. SAMEA Biosimilar Monoclonal Antibodies Sales by Application (2021-2026) & (K Units) Table 205. SAMEA Biosimilar Monoclonal Antibodies Sales by Application (2027-2032) & (K Units) Table 206. SAMEA Biosimilar Monoclonal Antibodies Sales Price by Application (2021-2026) & (USD/Unit) Table 207. SAMEA Biosimilar Monoclonal Antibodies Sales Price by Application (2027-2032) & (USD/Unit) Table 208. SAMEA Biosimilar Monoclonal Antibodies Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 209. SAMEA Biosimilar Monoclonal Antibodies Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 210. SAMEA Biosimilar Monoclonal Antibodies Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 211. SAMEA Biosimilar Monoclonal Antibodies Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 212. SAMEA Biosimilar Monoclonal Antibodies Sales by Country (2021-2026) & (K Units) Table 213. SAMEA Biosimilar Monoclonal Antibodies Sales by Country (2027-2032) & (K Units) Table 214. SAMEA Biosimilar Monoclonal Antibodies Sales Price by Country (2021-2026) & (USD/Unit) Table 215. SAMEA Biosimilar Monoclonal Antibodies Sales Price by Country (2027-2032) & (USD/Unit) Table 216. Brazil Biosimilar Monoclonal Antibodies Revenue (2021-2032) & (US$ Million) Table 217. Argentina Biosimilar Monoclonal Antibodies Revenue (2021-2032) & (US$ Million) Table 218. Chile Biosimilar Monoclonal Antibodies Revenue (2021-2032) & (US$ Million) Table 219. Colombia Biosimilar Monoclonal Antibodies Revenue (2021-2032) & (US$ Million) Table 220. Peru Biosimilar Monoclonal Antibodies Revenue (2021-2032) & (US$ Million) Table 221. Saudi Arabia Biosimilar Monoclonal Antibodies Revenue (2021-2032) & (US$ Million) Table 222. Israel Biosimilar Monoclonal Antibodies Revenue (2021-2032) & (US$ Million) Table 223. UAE Biosimilar Monoclonal Antibodies Revenue (2021-2032) & (US$ Million) Table 224. Turkey Biosimilar Monoclonal Antibodies Revenue (2021-2032) & (US$ Million) Table 225. Iran Biosimilar Monoclonal Antibodies Revenue (2021-2032) & (US$ Million) Table 226. Egypt Biosimilar Monoclonal Antibodies Revenue (2021-2032) & (US$ Million) Table 227. Key Raw Materials Table 228. Raw Materials Key Suppliers Table 229. Biosimilar Monoclonal Antibodies Distributors List Table 230. Biosimilar Monoclonal Antibodies Customers List Table 231. Research Programs/Design for This Report Table 232. Authors List of This Report Table 233. Secondary Sources Table 234. Primary Sources List of Figures Figure 1. Biosimilar Monoclonal Antibodies Image Figure 2. Global Biosimilar Monoclonal Antibodies Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Biosimilar Monoclonal Antibodies Market Size Share 2021 VS 2025 VS 2032 Figure 4. Infliximab Image Figure 5. Rituximab Image Figure 6. Trastuzumab Image Figure 7. Adalimumab Image Figure 8. Other Image Figure 9. Global Biosimilar Monoclonal Antibodies Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 10. Global Biosimilar Monoclonal Antibodies Market Size Share 2021 VS 2025 VS 2032 Figure 11. Oncology Image Figure 12. Autoimmune Disease Image Figure 13. Other Image Figure 14. Global Biosimilar Monoclonal Antibodies Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 15. Global Biosimilar Monoclonal Antibodies Revenue (2021-2032) & (US$ Million) Figure 16. Global Biosimilar Monoclonal Antibodies Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 17. Global Biosimilar Monoclonal Antibodies Revenue Market Share by Region: 2025 Versus 2032 Figure 18. Global Biosimilar Monoclonal Antibodies Revenue Market Share by Region (2021-2032) Figure 19. Global Biosimilar Monoclonal Antibodies Sales (2021-2032) & (K Units) Figure 20. Global Biosimilar Monoclonal Antibodies Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 21. Global Biosimilar Monoclonal Antibodies Sales Market Share by Region (2021-2032) Figure 22. US & Canada & Mexico Biosimilar Monoclonal Antibodies Sales YoY (2021-2032) & (K Units) Figure 23. Europe Biosimilar Monoclonal Antibodies Sales YoY (2021-2032) & (K Units) Figure 24. China Biosimilar Monoclonal Antibodies Sales YoY (2021-2032) & (K Units) Figure 25. Asia (Excluding China) Biosimilar Monoclonal Antibodies Sales YoY (2021-2032) & (K Units) Figure 26. South America, Middle East and Africa Biosimilar Monoclonal Antibodies Sales YoY (2021-2032) & (K Units) Figure 27. Global Biosimilar Monoclonal Antibodies Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 28. Global Biosimilar Monoclonal Antibodies Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 29. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 30. Global Biosimilar Monoclonal Antibodies Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 31. Global Biosimilar Monoclonal Antibodies Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 32. Global Biosimilar Monoclonal Antibodies Revenue Market Share by Type (2021-2032) Figure 33. Global Biosimilar Monoclonal Antibodies Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 34. Global Biosimilar Monoclonal Antibodies Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 35. Global Biosimilar Monoclonal Antibodies Sales Market Share by Type (2021-2032) Figure 36. Global Biosimilar Monoclonal Antibodies Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 37. Global Biosimilar Monoclonal Antibodies Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 38. Global Biosimilar Monoclonal Antibodies Revenue Market Share by Application (2021-2032) Figure 39. Global Biosimilar Monoclonal Antibodies Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 40. Global Biosimilar Monoclonal Antibodies Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 41. Global Biosimilar Monoclonal Antibodies Sales Market Share by Application (2021-2032) Figure 42. North America Biosimilar Monoclonal Antibodies Revenue Share by Type (2021-2032) Figure 43. North America Biosimilar Monoclonal Antibodies Sales Share by Type (2021-2032) Figure 44. North America Biosimilar Monoclonal Antibodies Revenue Share by Application (2021-2032) Figure 45. North America Biosimilar Monoclonal Antibodies Sales Share by Application (2021-2032) Figure 46. North America Biosimilar Monoclonal Antibodies Revenue Share by Country (2021-2032) Figure 47. North America Biosimilar Monoclonal Antibodies Sales Share by Country (2021-2032) Figure 48. Europe Biosimilar Monoclonal Antibodies Revenue Share by Type (2021-2032) Figure 49. Europe Biosimilar Monoclonal Antibodies Sales Share by Type (2021-2032) Figure 50. Europe Biosimilar Monoclonal Antibodies Revenue Share by Application (2021-2032) Figure 51. Europe Biosimilar Monoclonal Antibodies Sales Share by Application (2021-2032) Figure 52. Europe Biosimilar Monoclonal Antibodies Revenue Share by Country (2021-2032) Figure 53. Europe Biosimilar Monoclonal Antibodies Sales Share by Country (2021-2032) Figure 54. China Biosimilar Monoclonal Antibodies Revenue Share by Type (2021-2032) Figure 55. China Biosimilar Monoclonal Antibodies Sales Share by Type (2021-2032) Figure 56. China Biosimilar Monoclonal Antibodies Revenue Share by Application (2021-2032) Figure 57. China Biosimilar Monoclonal Antibodies Sales Share by Application (2021-2032) Figure 58. Asia Biosimilar Monoclonal Antibodies Revenue Share by Type (2021-2032) Figure 59. Asia Biosimilar Monoclonal Antibodies Sales Share by Type (2021-2032) Figure 60. Asia Biosimilar Monoclonal Antibodies Revenue Share by Application (2021-2032) Figure 61. Asia Biosimilar Monoclonal Antibodies Sales Share by Application (2021-2032) Figure 62. Asia Biosimilar Monoclonal Antibodies Revenue Share by Country (2021-2032) Figure 63. Asia Biosimilar Monoclonal Antibodies Sales Share by Country (2021-2032) Figure 64. SAMEA Biosimilar Monoclonal Antibodies Revenue Share by Type (2021-2032) Figure 65. SAMEA Biosimilar Monoclonal Antibodies Sales Share by Type (2021-2032) Figure 66. SAMEA Biosimilar Monoclonal Antibodies Revenue Share by Application (2021-2032) Figure 67. SAMEA Biosimilar Monoclonal Antibodies Sales Share by Application (2021-2032) Figure 68. SAMEA Biosimilar Monoclonal Antibodies Revenue Share by Country (2021-2032) Figure 69. SAMEA Biosimilar Monoclonal Antibodies Sales Share by Country (2021-2032) Figure 70. Biosimilar Monoclonal Antibodies Value Chain Figure 71. Manufacturing Cost Structure Figure 72. Biosimilar Monoclonal Antibodies Production Mode & Process Figure 73. Direct Comparison with Distribution Share Figure 74. Distributors Profiles Figure 75. Years Considered Figure 76. Research Process Figure 77. Key Executives Interviewed

Scope & coverage.

Types
  • Infliximab
  • Rituximab
  • Trastuzumab
  • Adalimumab
  • Other
Applications
  • Oncology
  • Autoimmune Disease
  • Other
Companies covered
  • Celltrion
  • Pfizer (Hospira)
  • 3SBIO
  • Novartis (Sandoz)
  • Dr Reddy’s
  • Celgen Biopharma
  • Cadila Healthcare
  • Hisun Pharma
  • Torrent Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Biosimilar Monoclonal Antibodies Market by Type
  3. 1.2.1 Global Biosimilar Monoclonal Antibodies Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Infliximab
  5. 1.2.3 Rituximab
  6. 1.2.4 Trastuzumab
  7. 1.2.5 Adalimumab
  8. 1.2.6 Other
  9. 1.3 Biosimilar Monoclonal Antibodies Market by Application
  10. 1.3.1 Global Biosimilar Monoclonal Antibodies Market Size by Application, 2021 VS 2025 VS 2032
  11. 1.3.2 Oncology
  12. 1.3.3 Autoimmune Disease
  13. 1.3.4 Other
  14. 1.4 Assumptions and Limitations
  15. 1.5 Study Goals and Objectives
2 Biosimilar Monoclonal Antibodies Market Dynamics
  1. 2.1 Biosimilar Monoclonal Antibodies Industry Trends
  2. 2.2 Biosimilar Monoclonal Antibodies Industry Drivers
  3. 2.3 Biosimilar Monoclonal Antibodies Industry Opportunities and Challenges
  4. 2.4 Biosimilar Monoclonal Antibodies Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Biosimilar Monoclonal Antibodies Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Biosimilar Monoclonal Antibodies Revenue by Region
  3. 3.2.1 Global Biosimilar Monoclonal Antibodies Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Biosimilar Monoclonal Antibodies Revenue by Region (2021-2026)
  5. 3.2.3 Global Biosimilar Monoclonal Antibodies Revenue by Region (2027-2032)
  6. 3.2.4 Global Biosimilar Monoclonal Antibodies Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Biosimilar Monoclonal Antibodies Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Biosimilar Monoclonal Antibodies Sales by Region
  9. 3.4.1 Global Biosimilar Monoclonal Antibodies Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Biosimilar Monoclonal Antibodies Sales by Region (2021-2026)
  11. 3.4.3 Global Biosimilar Monoclonal Antibodies Sales by Region (2027-2032)
  12. 3.4.4 Global Biosimilar Monoclonal Antibodies Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Biosimilar Monoclonal Antibodies Revenue by Manufacturers
  2. 4.1.1 Global Biosimilar Monoclonal Antibodies Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Biosimilar Monoclonal Antibodies Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Biosimilar Monoclonal Antibodies Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Biosimilar Monoclonal Antibodies Sales by Manufacturers
  6. 4.2.1 Global Biosimilar Monoclonal Antibodies Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Biosimilar Monoclonal Antibodies Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Biosimilar Monoclonal Antibodies Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Biosimilar Monoclonal Antibodies Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Biosimilar Monoclonal Antibodies Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Biosimilar Monoclonal Antibodies Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Biosimilar Monoclonal Antibodies Manufacturers, Product Type & Application
  13. 4.7 Global Biosimilar Monoclonal Antibodies Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Biosimilar Monoclonal Antibodies Market CR5 and HHI
  16. 4.8.2 2025 Biosimilar Monoclonal Antibodies Tier 1, Tier 2, and Tier 3
5 Biosimilar Monoclonal Antibodies Market by Type
  1. 5.1 Global Biosimilar Monoclonal Antibodies Revenue by Type
  2. 5.1.1 Global Biosimilar Monoclonal Antibodies Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Biosimilar Monoclonal Antibodies Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Biosimilar Monoclonal Antibodies Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Biosimilar Monoclonal Antibodies Sales by Type
  6. 5.2.1 Global Biosimilar Monoclonal Antibodies Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Biosimilar Monoclonal Antibodies Sales by Type (2021-2032) & (K Units)
  8. 5.2.3 Global Biosimilar Monoclonal Antibodies Sales Market Share by Type (2021-2032)
  9. 5.3 Global Biosimilar Monoclonal Antibodies Price by Type
6 Biosimilar Monoclonal Antibodies Market by Application
  1. 6.1 Global Biosimilar Monoclonal Antibodies Revenue by Application
  2. 6.1.1 Global Biosimilar Monoclonal Antibodies Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Biosimilar Monoclonal Antibodies Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Biosimilar Monoclonal Antibodies Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Biosimilar Monoclonal Antibodies Sales by Application
  6. 6.2.1 Global Biosimilar Monoclonal Antibodies Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Biosimilar Monoclonal Antibodies Sales by Application (2021-2032) & (K Units)
  8. 6.2.3 Global Biosimilar Monoclonal Antibodies Sales Market Share by Application (2021-2032)
  9. 6.3 Global Biosimilar Monoclonal Antibodies Price by Application
7 Company Profiles
  1. 7.1 Celltrion
  2. 7.1.1 Celltrion Company Information
  3. 7.1.2 Celltrion Business Overview
  4. 7.1.3 Celltrion Biosimilar Monoclonal Antibodies Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Celltrion Biosimilar Monoclonal Antibodies Product Portfolio
  6. 7.1.5 Celltrion Recent Developments
  7. 7.2 Pfizer (Hospira)
  8. 7.2.1 Pfizer (Hospira) Company Information
  9. 7.2.2 Pfizer (Hospira) Business Overview
  10. 7.2.3 Pfizer (Hospira) Biosimilar Monoclonal Antibodies Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Pfizer (Hospira) Biosimilar Monoclonal Antibodies Product Portfolio
  12. 7.2.5 Pfizer (Hospira) Recent Developments
  13. 7.3 3SBIO
  14. 7.3.1 3SBIO Company Information
  15. 7.3.2 3SBIO Business Overview
  16. 7.3.3 3SBIO Biosimilar Monoclonal Antibodies Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 3SBIO Biosimilar Monoclonal Antibodies Product Portfolio
  18. 7.3.5 3SBIO Recent Developments
  19. 7.4 Novartis (Sandoz)
  20. 7.4.1 Novartis (Sandoz) Company Information
  21. 7.4.2 Novartis (Sandoz) Business Overview
  22. 7.4.3 Novartis (Sandoz) Biosimilar Monoclonal Antibodies Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Novartis (Sandoz) Biosimilar Monoclonal Antibodies Product Portfolio
  24. 7.4.5 Novartis (Sandoz) Recent Developments
  25. 7.5 Dr Reddy’s
  26. 7.5.1 Dr Reddy’s Company Information
  27. 7.5.2 Dr Reddy’s Business Overview
  28. 7.5.3 Dr Reddy’s Biosimilar Monoclonal Antibodies Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Dr Reddy’s Biosimilar Monoclonal Antibodies Product Portfolio
  30. 7.5.5 Dr Reddy’s Recent Developments
  31. 7.6 Celgen Biopharma
  32. 7.6.1 Celgen Biopharma Company Information
  33. 7.6.2 Celgen Biopharma Business Overview
  34. 7.6.3 Celgen Biopharma Biosimilar Monoclonal Antibodies Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Celgen Biopharma Biosimilar Monoclonal Antibodies Product Portfolio
  36. 7.6.5 Celgen Biopharma Recent Developments
  37. 7.7 Cadila Healthcare
  38. 7.7.1 Cadila Healthcare Company Information
  39. 7.7.2 Cadila Healthcare Business Overview
  40. 7.7.3 Cadila Healthcare Biosimilar Monoclonal Antibodies Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Cadila Healthcare Biosimilar Monoclonal Antibodies Product Portfolio
  42. 7.7.5 Cadila Healthcare Recent Developments
  43. 7.8 Hisun Pharma
  44. 7.8.1 Hisun Pharma Company Information
  45. 7.8.2 Hisun Pharma Business Overview
  46. 7.8.3 Hisun Pharma Biosimilar Monoclonal Antibodies Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 Hisun Pharma Biosimilar Monoclonal Antibodies Product Portfolio
  48. 7.8.5 Hisun Pharma Recent Developments
  49. 7.9 Torrent Pharmaceuticals
  50. 7.9.1 Torrent Pharmaceuticals Company Information
  51. 7.9.2 Torrent Pharmaceuticals Business Overview
  52. 7.9.3 Torrent Pharmaceuticals Biosimilar Monoclonal Antibodies Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 Torrent Pharmaceuticals Biosimilar Monoclonal Antibodies Product Portfolio
  54. 7.9.5 Torrent Pharmaceuticals Recent Developments
8 North America
  1. 8.1 North America Biosimilar Monoclonal Antibodies Market Size by Type
  2. 8.1.1 North America Biosimilar Monoclonal Antibodies Revenue by Type (2021-2032)
  3. 8.1.2 North America Biosimilar Monoclonal Antibodies Sales by Type (2021-2032)
  4. 8.1.3 North America Biosimilar Monoclonal Antibodies Price by Type (2021-2032)
  5. 8.2 North America Biosimilar Monoclonal Antibodies Market Size by Application
  6. 8.2.1 North America Biosimilar Monoclonal Antibodies Revenue by Application (2021-2032)
  7. 8.2.2 North America Biosimilar Monoclonal Antibodies Sales by Application (2021-2032)
  8. 8.2.3 North America Biosimilar Monoclonal Antibodies Price by Application (2021-2032)
  9. 8.3 North America Biosimilar Monoclonal Antibodies Market Size by Country
  10. 8.3.1 North America Biosimilar Monoclonal Antibodies Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Biosimilar Monoclonal Antibodies Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Biosimilar Monoclonal Antibodies Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
  15. 8.3.6 Mexico
9 Europe
  1. 9.1 Europe Biosimilar Monoclonal Antibodies Market Size by Type
  2. 9.1.1 Europe Biosimilar Monoclonal Antibodies Revenue by Type (2021-2032)
  3. 9.1.2 Europe Biosimilar Monoclonal Antibodies Sales by Type (2021-2032)
  4. 9.1.3 Europe Biosimilar Monoclonal Antibodies Price by Type (2021-2032)
  5. 9.2 Europe Biosimilar Monoclonal Antibodies Market Size by Application
  6. 9.2.1 Europe Biosimilar Monoclonal Antibodies Revenue by Application (2021-2032)
  7. 9.2.2 Europe Biosimilar Monoclonal Antibodies Sales by Application (2021-2032)
  8. 9.2.3 Europe Biosimilar Monoclonal Antibodies Price by Application (2021-2032)
  9. 9.3 Europe Biosimilar Monoclonal Antibodies Market Size by Country
  10. 9.3.1 Europe Biosimilar Monoclonal Antibodies Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Biosimilar Monoclonal Antibodies Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Biosimilar Monoclonal Antibodies Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Russia
  18. 9.3.9 Spain
  19. 9.3.10 Netherlands
10 China
  1. 10.1 China Biosimilar Monoclonal Antibodies Market Size by Type
  2. 10.1.1 China Biosimilar Monoclonal Antibodies Revenue by Type (2021-2032)
  3. 10.1.2 China Biosimilar Monoclonal Antibodies Sales by Type (2021-2032)
  4. 10.1.3 China Biosimilar Monoclonal Antibodies Price by Type (2021-2032)
  5. 10.2 China Biosimilar Monoclonal Antibodies Market Size by Application
  6. 10.2.1 China Biosimilar Monoclonal Antibodies Revenue by Application (2021-2032)
  7. 10.2.2 China Biosimilar Monoclonal Antibodies Sales by Application (2021-2032)
  8. 10.2.3 China Biosimilar Monoclonal Antibodies Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Biosimilar Monoclonal Antibodies Market Size by Type
  2. 11.1.1 Asia Biosimilar Monoclonal Antibodies Revenue by Type (2021-2032)
  3. 11.1.2 Asia Biosimilar Monoclonal Antibodies Sales by Type (2021-2032)
  4. 11.1.3 Asia Biosimilar Monoclonal Antibodies Price by Type (2021-2032)
  5. 11.2 Asia Biosimilar Monoclonal Antibodies Market Size by Application
  6. 11.2.1 Asia Biosimilar Monoclonal Antibodies Revenue by Application (2021-2032)
  7. 11.2.2 Asia Biosimilar Monoclonal Antibodies Sales by Application (2021-2032)
  8. 11.2.3 Asia Biosimilar Monoclonal Antibodies Price by Application (2021-2032)
  9. 11.3 Asia Biosimilar Monoclonal Antibodies Market Size by Country
  10. 11.3.1 Asia Biosimilar Monoclonal Antibodies Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Biosimilar Monoclonal Antibodies Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Biosimilar Monoclonal Antibodies Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Biosimilar Monoclonal Antibodies Market Size by Type
  2. 12.1.1 SAMEA Biosimilar Monoclonal Antibodies Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Biosimilar Monoclonal Antibodies Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Biosimilar Monoclonal Antibodies Price by Type (2021-2032)
  5. 12.2 SAMEA Biosimilar Monoclonal Antibodies Market Size by Application
  6. 12.2.1 SAMEA Biosimilar Monoclonal Antibodies Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Biosimilar Monoclonal Antibodies Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Biosimilar Monoclonal Antibodies Price by Application (2021-2032)
  9. 12.3 SAMEA Biosimilar Monoclonal Antibodies Market Size by Country
  10. 12.3.1 SAMEA Biosimilar Monoclonal Antibodies Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Biosimilar Monoclonal Antibodies Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Biosimilar Monoclonal Antibodies Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Biosimilar Monoclonal Antibodies Value Chain Analysis
  2. 13.1.1 Biosimilar Monoclonal Antibodies Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Biosimilar Monoclonal Antibodies Production Mode & Process
  6. 13.2 Biosimilar Monoclonal Antibodies Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Biosimilar Monoclonal Antibodies Distributors
  9. 13.2.3 Biosimilar Monoclonal Antibodies Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst